Kidneys, heart and diabetes: Science and practice – Part 2

John Deanfield is Professor of Cardiology at University College London (UCL) and Consultant Cardiologist at the Barts Heart Centre (BHC) London UK.   He is the Director of National Institute for Cardiovascular (CV) Outcomes Research (NICOR) which incorporates the national databases for cardiovascular outcomes. Professor Deanfield undertook his undergraduate training at Churchill College, Cambridge and the Middlesex Hospital, London and subsequently trained at the Hammersmith and Great Ormond Street Hospitals. His principal interests are vascular medicine, opportunities for lifetime management of cardiovascular risk and large scale cardiovascular outcomes research.  He has been at the forefront in describing the impact of obesity, cholesterol, diabetes, smoking and other risk factors on health in later life, through coordination of multiple large longitudinal cardiovascular studies in population throughout lifetime. He Chaired the Joint British Societies (JBS3) National Guidelines for Cardiovascular Disease Prevention (2014) and in collaboration with Public Health England, NHS Choices and NHS England led the development of the public facing Heart Age Tool first launched in January 2015.   He was awarded the British Cardiac Society McKenzie Award, and the John Hopkins All Children’s Hospital Decades of Service Award in 2017.  He currently Chairs the UK’s National Health Check Programme Review (2020) and is Chief Medical Advisor to the new national Early Disease Detection programme (2020). Professor Deanfield serves on many international advisory boards and is a member of the editorial boards of several major CV journals, as well as Associate Editor of the European Heart Journal. He has published numerous articles in leading medical and scientific journals such as New England Journal of Medicine, The Lancet, Circulation and European Heart Journal.  Papers published: 484 Citations: >100K H index: 131.

Professor Gerry McKay is a Consultant Physician & Clinical Pharmacologist at Glasgow Royal Infirmary, an Honorary Clinical Assoicate Professor at the University of Glasgow and Visiting Professor at the University of Strathclyde. He is currently lead clinician for an evolving Department of Diabetes, Endocrinology and Clinical Pharmacology in Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow specialising in the care of those with Type 2 diabetes including being lead for a specialist clinical for patients with diabetic nephropathy. He has a commitment to safe and rational prescribing with involvement in undergraduate and postgraduate education.  He was involved in the development off SIGN guidelines including the therapeutics update in 2017. He has co-edited a book on SGLT-2 inhibitors, the last 2 editions of Lecture Notes in Clinical Pharmacology & Therapeutics and published many papers in the area of therapeutics and diabetes.

Clinician scientist based at the Royal Free Hospital with an interest in chronic kidney disease (CKD) and its complications. Has been involved in many randomised controlled trials in patients with CKD assessing lipid lowering therapies, calcimimetics, intravenous iron and SGLT2 inhibitors. Co-principle investigator of the DAPA-CKD trial.